Multi-particulates offer precise control over drug release profiles, making them ideal for modified release pattern. We specialize in manufacturing pellets with various release profiles (immediate, delayed, controlled, sustained, targeted, etc.), which help reduce dosage frequency, and minimize side effects, thereby enhancing patient convenience.

Directly compressible granules are crucial in tablet manufacturing, ensuring a seamless transition to the final product. Utilizing our cutting-edge technology, we specialize in producing these granules, particularly with modified release profiles. Our advanced technological solutions empower PFI customers to address unmet medical needs in their markets.

Masking bitter tastes in oral drugs for special patient populations is a challenge we have mastered. Our taste masking techniques, which do not affect drug efficacy or shelf life. are applied to product like dry powders and orally disintegrating films, thereby enhancing patient compliance.

Oral Thin Films are dissolvable strips placed on the tongue for rapid medication delivery into the bloodstream, offering a convenient alternative to tablets or capsules. We are among the select few companies worldwide equipped with in-house technology for manufacturing Oral Thin Films.

Our patented Thinoral® technology produces instantly wettable, rapidly dissolving films that are non-sticky, non-tacky, and non-curving. Capable of loading up to 50-60 mg of active drug, this technology ensures uniform thinness, providing a large surface area for dissolution. It effectively addresses solubility issues associated with poorly soluble drugs and is suitable for delivering thermolabile medications.

MucoStrip® Technology offers a unique dosage form that is placed on the tongue and does not require water for administration.

Sublingual Technology involves administering drugs under the tongue for rapid absorption.

Bilayer Oral Thin Film Technology reduces pill burden by enabling the administration of two or more Active Pharmaceutical Ingredients (APIs) in a single Fixed – Dose Combination (FDC).

Combining Nanotechnology with Thinoral® Technology enhances drug bioavailability, particularly for poorly soluble drugs with crystalline Active Pharmaceutical Ingredients (APIs). This innovative approach addresses solubility challenges, resulting in improved drug delivery and therapeutic outcomes.

Our technology revolutionizes pharmaceutical processes by ensuring precise drug content uniformity and optimizing yield, particularly for controlled substances like opioids. It supports combination drug delivery, offering a comprehensive solution for precision and efficiency in manufacturing potent pharmaceuticals.

Our technology offers a non-invasive oral spray alternative to injectables, focusing on delivering large molecules such as peptides and hormonal therapies. It has been validated for effectiveness through proof-of-concept studies. Built on a proprietary, patented process, it is protected by patents in key regions, including the US, Canada, India, and Brazil, ensuring exclusivity and protection.

Used for the solubilization of oil-soluble drugs and liquids in the oil phase, this technology micro-emulsifies with an aqueous phase containing polymers to coat the substrate.

Used for heat-sensitive materials that either lose potency or transform into another form during processing at standard temperatures.

It is used for the release of drugs in pseudo-zero kinetics and serves as an alternative to OROS® technology.

Used for the release of drugs through pores into an aqueous medium.